menu
    • menu

    Company profile for Savara

    NEW Drugs in Dev: 7
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, AeroVanc and amikacin/fosfomycin. Molgradex is an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, and in Phase 2a development for nontuberculous mycobacteria, or NTM, in both non-cystic fibrosis (CF) and CF-affected individuals with chronic NTM lu...
    Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, AeroVanc and amikacin/fosfomycin. Molgradex is an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, and in Phase 2a development for nontuberculous mycobacteria, or NTM, in both non-cystic fibrosis (CF) and CF-affected individuals with chronic NTM lung infection. AeroVanc, is a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin-resistant Sstaphylococcus aureus, or MRSA, lung infection in CF.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SavaraUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Savara Inc. 6836 Bee Cave Road, Building 3, Suite 200 Austin, TX, 78746
    Telephone
    Telephone
    +1 (512) 614-1848
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://savarapharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/savara-pharmaceuticals
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/SavaraPharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Savara Announces New Employment Inducement Grant
    Savara Announces New Employment Inducement Grant

    13 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260213924701/en/Savara-Announces-New-Employment-Inducement-Grant

    BUSINESSWIRE
    13 Feb 2026
    Share Share
    Savara To Participate In Investor Healthcare Conferences
    Savara To Participate In Investor Healthcare Conferences

    04 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260204720441/en/Savara-Announces-Participation-in-Upcoming-Investor-Healthcare-Conferences

    BUSINESSWIRE
    04 Feb 2026
    Share Share
    Savara Amends Debt Facility; $75M After FDA Approval
    Savara Amends Debt Facility; $75M After FDA Approval

    27 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260127749473/en/Savara-Announces-Amendment-to-Hercules-Capital-Debt-Facility-Providing-up-to-%2475M-of-Additional-Debt-Funding-Upon-U.S.-Food-and-Drug-Administration-FDA-Approval-of-MOLBREEVI

    BUSINESSWIRE
    27 Jan 2026
    Share Share
    Savara Announces New Employment Inducement Grant
    Savara Announces New Employment Inducement Grant

    16 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260116552373/en/Savara-Announces-New-Employment-Inducement-Grant

    BUSINESSWIRE
    16 Jan 2026
    Share Share
    Savara Selects PANTHERx Rare as Exclusive U.S. Specialty Pharmacy
    Savara Selects PANTHERx Rare as Exclusive U.S. Specialty Pharmacy

    08 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260108735513/en/PANTHERx-Rare-Selected-by-Savara-as-the-U.S.-Exclusive-Specialty-Pharmacy-for-MOLBREEVI

    BUSINESSWIRE
    08 Jan 2026
    Share Share
    Savara Resubmits BLA for Molbreevi to Treat Autoimmune PAP
    Savara Resubmits BLA for Molbreevi to Treat Autoimmune PAP

    22 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251221214643/en/Savara-Resubmits-the-Biologics-License-Application-BLA-to-the-U.S.-Food-and-Drug-Administration-FDA-for-MOLBREEVI-for-the-Potential-Treatment-of-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP

    BUSINESSWIRE
    22 Dec 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search